Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 165Head & Neck 18Thoracic 15Tumor-Agnostic 8Genitourinary 7Breast 7Other solid neoplasm 6Gynecologic 5CNS 3Sarcoma 2Myeloid 1Endocrine 1

Conditions

Gliosarcoma 1Glioma 1Glioblastoma 1Advanced Solid Tumors 1

Interventions

Radiotherapy 215Cyclophosphamide 210Doxorubicin 207Temozolomide 181Ifosfamide 121Filgrastim 111Etoposide 101Imatinib Mesylate 99Vincristine 92Gemcitabine 89Bevacizumab 83Irinotecan 79Magnetic Resonance Spectroscopy 78pembrolizumab 75Radiation 66Carboplatin 65pazopanib 60Methotrexate 60Nivolumab 58Cisplatin 58fludarabine phosphate 56Peripheral Blood Stem Cell Transplantation 56Specimen Handling 53Docetaxel 50Busulfan 48Trabectedin 47Biopsy 47Melphalan 46Surgical Procedures, Operative 44Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Panitumumab × Sarcoma × Clear all
NCT04185883 2025-10-22

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Amgen

Phase 1 Active not recruiting
610 enrolled
Other solid neoplasmSarcoma

Advanced Solid Tumors

NCT01017653 2013-09-04

Panitumumab and Irinotecan for Malignant Gliomas

Duke University

Phase 2 Terminated
16 enrolled 9 charts
CNSSarcoma

Glioblastoma, Glioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡